HKSE:02190 (China)
Â
Class H
HK$
16.08
+0.10 (+0.63%)
Apr 11
What is a stock summary page? Click here for an overview.
Business Description
Zylox-Tonbridge Medical Technology Co Ltd
ISIN : CNE100004JD2
Share Class Description:
HKSE:02190: Class HCompare
Compare
Traded in other countries / regions
02190.Hong Kong818.Germany IPO Date
2021-07-05Description
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's main products include Thrombite Clot Retriever Device (Thrombite CRD) and Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB).
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.11 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 1.5 | |||||
| Interest Coverage | 48.91 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 8.89 | |||||
| Beneish M-Score | -2.07 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 159.1 | |||||
| 3-Year EBITDA Growth Rate | 25.2 | |||||
| 3-Year EPS without NRI Growth Rate | 14.7 | |||||
| 3-Year FCF Growth Rate | 13 | |||||
| 3-Year Book Growth Rate | 75.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 47.02 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.24 | |||||
| 9-Day RSI | 56.93 | |||||
| 14-Day RSI | 58.05 | |||||
| 3-1 Month Momentum % | 17.63 | |||||
| 6-1 Month Momentum % | 6.34 | |||||
| 12-1 Month Momentum % | 36.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.58 | |||||
| Quick Ratio | 3.96 | |||||
| Cash Ratio | 3.84 | |||||
| Days Inventory | 297.77 | |||||
| Days Sales Outstanding | 0.71 | |||||
| Days Payable | 97.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.2 | |||||
| Shareholder Yield % | 0.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.55 | |||||
| Operating Margin % | 7.63 | |||||
| Net Margin % | 12.84 | |||||
| FCF Margin % | 2.99 | |||||
| ROE % | 3.23 | |||||
| ROA % | 2.9 | |||||
| ROIC % | 2.96 | |||||
| 3-Year ROIIC % | -2.42 | |||||
| ROC (Joel Greenblatt) % | 9.71 | |||||
| ROCE % | 1.92 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 49.02 | |||||
| Forward PE Ratio | 31.83 | |||||
| PE Ratio without NRI | 48.88 | |||||
| PS Ratio | 6.29 | |||||
| PB Ratio | 1.55 | |||||
| Price-to-Tangible-Book | 1.57 | |||||
| Price-to-Free-Cash-Flow | 211.58 | |||||
| Price-to-Operating-Cash-Flow | 21.96 | |||||
| EV-to-EBIT | 59.6 | |||||
| EV-to-EBITDA | 59.28 | |||||
| EV-to-Revenue | 4.56 | |||||
| EV-to-FCF | 139.81 | |||||
| Price-to-GF-Value | 0.39 | |||||
| Price-to-Graham-Number | 1.85 | |||||
| Price-to-Net-Current-Asset-Value | 4.09 | |||||
| Price-to-Net-Cash | 5.17 | |||||
| Earnings Yield (Greenblatt) % | 1.68 | |||||
| FCF Yield % | 0.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zylox-Tonbridge Medical Technology Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 838.674 | ||
| EPS (TTM) (HK$) | 0.328 | ||
| Beta | 0.89 | ||
| 3-Year Sharpe Ratio | 0.34 | ||
| 3-Year Sortino Ratio | 0.53 | ||
| Volatility % | 38.34 | ||
| 14-Day RSI | 58.05 | ||
| 14-Day ATR (HK$) | 0.977671 | ||
| 20-Day SMA (HK$) | 15.53 | ||
| 12-1 Month Momentum % | 36.39 | ||
| 52-Week Range (HK$) | 8.62 - 16.9 | ||
| Shares Outstanding (Mil) | 318.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zylox-Tonbridge Medical Technology Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zylox-Tonbridge Medical Technology Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zylox-Tonbridge Medical Technology Co Ltd Frequently Asked Questions
What is Zylox-Tonbridge Medical Technology Co Ltd(HKSE:02190)'s stock price today?
The current price of HKSE:02190 is HK$16.08. The 52 week high of HKSE:02190 is HK$16.90 and 52 week low is HK$8.62.
When is next earnings date of Zylox-Tonbridge Medical Technology Co Ltd(HKSE:02190)?
The next earnings date of Zylox-Tonbridge Medical Technology Co Ltd(HKSE:02190) is .
Does Zylox-Tonbridge Medical Technology Co Ltd(HKSE:02190) pay dividends? If so, how much?
Zylox-Tonbridge Medical Technology Co Ltd(HKSE:02190) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers